Literature DB >> 1358870

Diagnostic efficacy of serum alkaline phosphatase and gamma-glutamyltransferase in dogs with histologically confirmed hepatobiliary disease: 270 cases (1980-1990).

S A Center1, M R Slater, T Manwarren, K Prymak.   

Abstract

The diagnostic efficacy of serum alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) activities was examined, using the records of 270 dogs initially suspected of having hepatobiliary disease on the basis of history, findings on physical examination, results of baseline screening tests, or any combination of these data. Histologic examination of hepatic tissue was performed in each dog. Sixty-three dogs did not have histologic evidence of hepatobiliary disease and served as the control group. On the basis of diagnosis, dogs were assigned to 1 of 8 groups: dogs with cirrhosis (n = 34), steroid hepatopathy (n = 16), hepatic neoplasia (primary and secondary, n = 36), chronic hepatitis (n = 14), chronic passive congestion (n = 5), hepatic necrosis (n = 17), portosystemic vascular anomaly (n = 35), and cholestasis (extrahepatic bile-duct obstruction and intrahepatic cholestasis, n = 50). Of the 207 dogs with hepatobiliary disease, 29 (14%) had normal ALP and GGT activities, 31 (15%) had normal ALP activity, and 112 (54%) had normal GGT activity. Of the 63 control dogs, 29 (46%) had normal serum ALP and GGT activities, 32 had normal ALP activity (ALP specificity, 51%), and 55 had normal GGT activity (GGT specificity, 87%). The specificity of ALP and GGT in parallel (positive result = result of either test abnormal) was 46%, and in series (positive result = results of both tests abnormal) was 91%. The highest median activities of ALP developed in dogs with cholestasis, steroid hepatopathy, chronic hepatitis, and hepatic necrosis. The highest median activities of GGT developed in dogs with steroid hepatopathy, cholestasis, and hepatic necrosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358870

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Liver biochemical and histopathological findings in dogs with experimentally induced exocrine pancreatic insufficiency.

Authors:  K K Adamama-Moraitou; T S Rallis; L G Papazoglou; A Papasteriadis; N Roubies; H Kaldrimidou; L S Leontides
Journal:  Can J Vet Res       Date:  2004-01       Impact factor: 1.310

2.  A descriptive study of the histopathologic and biochemical liver test abnormalities in dogs with liver disease in Thailand.

Authors:  Sathidpak N Assawarachan; Phudit Maneesaay; Naris Thengchaisri
Journal:  Can J Vet Res       Date:  2020-07       Impact factor: 1.310

3.  Sensitivity and Specificity of Plasma ALT, ALP, and Bile Acids for Hepatitis in Labrador Retrievers.

Authors:  K Dirksen; I A Burgener; J Rothuizen; T S G A M van den Ingh; L C Penning; B Spee; H Fieten
Journal:  J Vet Intern Med       Date:  2017-05-23       Impact factor: 3.333

4.  Evaluation of hepatobiliary ultrasound scores in healthy dogs and dogs with liver diseases.

Authors:  Sathidpak Nantasanti Assawarachan; Piyathip Chuchalermporn; Phudit Maneesaay; Naris Thengchaisri
Journal:  Vet World       Date:  2019-08-17

5.  Thyroid function and serum hepatic enzyme activity in dogs after phenobarbital administration.

Authors:  T L Gieger; G Hosgood; J Taboada; K J Wolfsheimer; P B Mueller
Journal:  J Vet Intern Med       Date:  2000 May-Jun       Impact factor: 3.333

6.  Effects of long-term phenobarbital treatment on the liver in dogs.

Authors:  P B Müller; J Taboada; G Hosgood; B P Partington; J L VanSteenhouse; H W Taylor; K J Wolfsheimer
Journal:  J Vet Intern Med       Date:  2000 Mar-Apr       Impact factor: 3.333

7.  A multicenter retrospective study assessing progression of biliary sludge in dogs using ultrasonography.

Authors:  Thomas Butler; Nick Bexfield; Cecile Dor; Nicoletta Fantaconi; Iris Heinsoo; Darren Kelly; Andrew Kent; Matthew Pack; Susanna J Spence; Patricia M Ward; Penny Watson; Katie E McCallum
Journal:  J Vet Intern Med       Date:  2022-04-15       Impact factor: 3.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.